Browse FSTL4

Summary
SymbolFSTL4
Namefollistatin-like 4
Aliases KIAA1061; follistatin-like protein 4; Follistatin-related protein 4
Chromosomal Location5q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted
Domain PF07648 Kazal-type serine protease inhibitor domain
Function

-

> Gene Ontology
 
Biological Process GO:0001558 regulation of cell growth
GO:0007409 axonogenesis
GO:0008361 regulation of cell size
GO:0010721 negative regulation of cell development
GO:0010769 regulation of cell morphogenesis involved in differentiation
GO:0010771 negative regulation of cell morphogenesis involved in differentiation
GO:0010975 regulation of neuron projection development
GO:0010977 negative regulation of neuron projection development
GO:0016049 cell growth
GO:0016358 dendrite development
GO:0022604 regulation of cell morphogenesis
GO:0030308 negative regulation of cell growth
GO:0031345 negative regulation of cell projection organization
GO:0031547 brain-derived neurotrophic factor receptor signaling pathway
GO:0031548 regulation of brain-derived neurotrophic factor receptor signaling pathway
GO:0031549 negative regulation of brain-derived neurotrophic factor receptor signaling pathway
GO:0032535 regulation of cellular component size
GO:0045665 negative regulation of neuron differentiation
GO:0045926 negative regulation of growth
GO:0048588 developmental cell growth
GO:0048638 regulation of developmental growth
GO:0048640 negative regulation of developmental growth
GO:0048667 cell morphogenesis involved in neuron differentiation
GO:0048668 collateral sprouting
GO:0048670 regulation of collateral sprouting
GO:0048671 negative regulation of collateral sprouting
GO:0050768 negative regulation of neurogenesis
GO:0050770 regulation of axonogenesis
GO:0050771 negative regulation of axonogenesis
GO:0050773 regulation of dendrite development
GO:0051961 negative regulation of nervous system development
GO:0060560 developmental growth involved in morphogenesis
GO:0060996 dendritic spine development
GO:0060998 regulation of dendritic spine development
GO:0061000 negative regulation of dendritic spine development
GO:0061387 regulation of extent of cell growth
GO:0061564 axon development
GO:0090066 regulation of anatomical structure size
GO:2000171 negative regulation of dendrite development
Molecular Function GO:0019838 growth factor binding
GO:0043121 neurotrophin binding
GO:0048403 brain-derived neurotrophic factor binding
Cellular Component GO:0030141 secretory granule
GO:0099503 secretory vesicle
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolFSTL4
Namefollistatin-like 4
Aliases KIAA1061; follistatin-like protein 4; Follistatin-related protein 4
Chromosomal Location5q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between FSTL4 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolFSTL4
Namefollistatin-like 4
Aliases KIAA1061; follistatin-like protein 4; Follistatin-related protein 4
Chromosomal Location5q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of FSTL4 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolFSTL4
Namefollistatin-like 4
Aliases KIAA1061; follistatin-like protein 4; Follistatin-related protein 4
Chromosomal Location5q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of FSTL4 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.3050.255
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.6810.19
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0220.955
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2660.67
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 591.0060.478
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.6720.686
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.3080.621
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.550.543
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0480.96
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.2050.693
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.1670.815
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0970.797
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of FSTL4 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277318.51.417.10.00519
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275918.51.716.80.0108
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolFSTL4
Namefollistatin-like 4
Aliases KIAA1061; follistatin-like protein 4; Follistatin-related protein 4
Chromosomal Location5q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FSTL4. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolFSTL4
Namefollistatin-like 4
Aliases KIAA1061; follistatin-like protein 4; Follistatin-related protein 4
Chromosomal Location5q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FSTL4. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FSTL4.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolFSTL4
Namefollistatin-like 4
Aliases KIAA1061; follistatin-like protein 4; Follistatin-related protein 4
Chromosomal Location5q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FSTL4. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolFSTL4
Namefollistatin-like 4
Aliases KIAA1061; follistatin-like protein 4; Follistatin-related protein 4
Chromosomal Location5q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of FSTL4 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolFSTL4
Namefollistatin-like 4
Aliases KIAA1061; follistatin-like protein 4; Follistatin-related protein 4
Chromosomal Location5q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between FSTL4 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolFSTL4
Namefollistatin-like 4
Aliases KIAA1061; follistatin-like protein 4; Follistatin-related protein 4
Chromosomal Location5q31.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting FSTL4 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.